Delivery Order SPE2DB22D1017-SPE2DB25FG7RL
- Not listed
- The Defense Logistics Agency awarded a $1,562.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on March 11, 2025, for the supply of Medroxyprogesterone 150 mg/ml with an ultimate completion date of March 12, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed at the...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a $1,003.18 delivery order to AmerisourceBergen Drug Corp for medroxyprogesterone on September 13, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside procurement executed under the company's existing contract vehicle. The work will be performed at the vendor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,649.15 to AmerisourceBergen Drug Corp for the supply of Medroxyprogesterone 150 mg/mL, a hormone-based pharmaceutical product. This non-competitive delivery order, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, utilizes firm fixed-price pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $34,140.26 firm fixed-price delivery order is for the supply of medroxyprogesterone 150 mg/ml, a pharmaceutical product. The contract has an ultimate completion date of January 9, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- The Defense Logistics Agency awarded a $1,253.23 delivery order to AmerisourceBergen Drug Corp for Medroxyprogesterone 150 mg/mL, a hormone treatment medication. This non-set-aside, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and is classified as a firm fixed price delivery order. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,839.57 to AmerisourceBergen Drug Corp for the supply of Medroxyprogesterone 150 mg/ml. This competitive award, issued on September 4, 2025, carries a firm fixed price structure with performance completion targeted for September 5, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery order is issued under...
- The Defense Logistics Agency awarded a $12,600 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 150 mg/ml medroxyprogesterone. As the prime contractor, Amerisourcebergen will supply the pharmaceutical product to the DLA under a one-day contract spanning August 24-25, 2023. Amerisourcebergen, a subsidiary of Amerisourcebergen Corporation, will perform the order from its facility in Conshohocken, Pennsylvania. No subcontractors or set aside designations were identified....
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,332.20 firm fixed-price contract is for the delivery of 4,568,260,604 milliliters of the drug medroxyprogesterone 150 mg/mL. The contract has an ultimate completion date of May 16, 2025 and is not designated as a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Medroxyprogesterone 150 mg/mL. The contract has a ceiling value of $2,309.68 and was awarded on September 20, 2022, with a completion date of September 21, 2022. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of Medroxyprogesterone 150 mg/mL. The contract has a firm fixed price, with a ceiling value of $3,016.81, and a performance period through July 3, 2025. The contract is not set aside and was awarded on July 2, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG7RLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,123.41 to AmerisourceBergen Drug Corp for the supply of Medroxyprogesterone 150 mg/mL, a synthetic progestin used in hormone therapy and contraceptive applications. This firm fixed-price contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical. The contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare systems. The company holds a comprehensive IDC valued at $999,999,999.00 through December 2026, which functions as a global pharmaceutical support vehicle enabling the supply of diverse pharmaceutical products, medical devices, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs. This delivery order for Medroxyprogesterone reflects the company's extensive portfolio of competitive, non-set-aside federal medical supply contracts with DLA, demonstrating its capability to fulfill federal procurement requirements for both routine and specialized pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 7/18/25 |